Seroatlas · Human Serome Atlas

LYPLA1

Acyl-protein thioesterase 1

Also known as: APT-1, LPL1, LYPA1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O75608
Gene: LYPLA1
Ensembl: ENSG00000120992
Chromosome: 8
Canonical length: 230 aa
Protein class: Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Nucleoplasm,Cytosol
Quaternary structure: Homodimer

OverviewNCBI Gene

This gene encodes a member of the alpha/beta hydrolase superfamily. The encoded protein functions as a homodimer, exhibiting both depalmitoylating as well as lysophospholipase activity, and may be involved in Ras localization and signaling. Alternate splicing results in multiple transcript variants. Pseudogenes of this gene have been defined on chromosomes 4, 6, and 7. [provided by RefSeq, Jul 2013]

Canonical amino-acid sequenceUniProt

230 residues, UniProt reviewed canonical sequence.

>O75608|LYPLA1
     1  MCGNNMSTPL PAIVPAARKA TAAVIFLHGL GDTGHGWAEA FAGIRSSHIK YICPHAPVRP
    61  VTLNMNVAMP SWFDIIGLSP DSQEDESGIK QAAENIKALI DQEVKNGIPS NRIILGGFSQ
   121  GGALSLYTAL TTQQKLAGVT ALSCWLPLRA SFPQGPIGGA NRDISILQCH GDCDPLVPLM
   181  FGSLTVEKLK TLVNPANVTF KTYEGMMHSS CQQEMMDVKQ FIDKLLPPID

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LYPLA1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.25
Highest tissue expression: 78 nTPM

Expression across tissuesHPA

Tissue

liver: 78 nTPM
tongue: 66 nTPM
testis: 61 nTPM
kidney: 59 nTPM
urinary bladder: 59 nTPM
esophagus: 52 nTPM

Single-cell type

late spermatids: 1,094 nCPM
early spermatids: 975 nCPM
esophageal apical cells: 887 nCPM
syncytiotrophoblasts: 544 nCPM
extravillous trophoblasts: 483 nCPM
parietal cells: 345 nCPM

Immune cell

eosinophil: 112 nTPM
non-classical monocyte: 109 nTPM
total PBMC: 99 nTPM
basophil: 94 nTPM
myeloid DC: 93 nTPM
classical monocyte: 81 nTPM

Brain region

choroid plexus: 26 nTPM
hypothalamus: 18 nTPM
cerebellum: 17 nTPM
thalamus: 17 nTPM
medulla oblongata: 17 nTPM
white matter: 16 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.09
gnomAD pLI: 0
gnomAD missense Z: 1.03
DepMap mean gene effect: -0.21
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 10% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LYPLA1 as an antibody target. Whether an autoantibody or antibody against LYPLA1 could matter depends on whether native LYPLA1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LYPLA1 is annotated at the cell surface, where native LYPLA1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LYPLA1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...